PMID- 25483650
OWN - NLM
STAT- MEDLINE
DCOM- 20151026
LR  - 20220105
IS  - 2164-554X (Electronic)
IS  - 2164-5515 (Print)
IS  - 2164-5515 (Linking)
VI  - 10
IP  - 11
DP  - 2014
TI  - Novel dendritic cell-based vaccination in late stage melanoma.
PG  - 3132-8
LID - 10.4161/hv.29110 [doi]
AB  - Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that play 
      an important role in stimulating an immune response of both CD4(+) T helper cells 
      and CD8(+) cytotoxic T lymphocytes (CTLs). As such, DCs have been studied 
      extensively in cancer immunotherapy for their capability to induce a specific 
      anti-tumor response when loaded with tumor antigens. However, when the most 
      relevant antigens of a tumor remain to be identified, alternative approaches are 
      required. Formation of a dentritoma, a fused DC and tumor cells hybrid, is one 
      strategy. Although initial studies of these hybrid cells are promising, several 
      limitations interfere with its clinical and commercial application. Here we 
      present early experience in clinical trials and an alternative approach to 
      manufacturing this DC/tumor cell hybrid for use in the treatment of late stage 
      and metastatic melanoma.
FAU - Schneble, Erika J
AU  - Schneble EJ
AD  - a San Antonio Military Medical Center; Department of General Surgery ; San 
      Antonio , TX USA.
FAU - Yu, Xianzhong
AU  - Yu X
FAU - Wagner, T E
AU  - Wagner TE
FAU - Peoples, George E
AU  - Peoples GE
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Hum Vaccin Immunother
JT  - Human vaccines & immunotherapeutics
JID - 101572652
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (IL2 protein, human)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Interleukin-2)
RN  - 0 (Ipilimumab)
RN  - 0 (Recombinant Proteins)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antigens, Neoplasm/immunology
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - Cancer Vaccines/immunology/*therapeutic use
MH  - Cell Fusion
MH  - Dendritic Cells/immunology/*transplantation
MH  - Humans
MH  - Hybrid Cells/*immunology/transplantation
MH  - Immunotherapy, Adoptive/*methods
MH  - Interferon alpha-2
MH  - Interferon-alpha/therapeutic use
MH  - Interleukin-2/therapeutic use
MH  - Ipilimumab
MH  - Melanoma/immunology/prevention & control/*therapy
MH  - Recombinant Proteins/therapeutic use
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Vaccination
PMC - PMC4514042
OTO - NOTNLM
OT  - adjuvant
OT  - cancer vaccine
OT  - dendritic cell
OT  - melanoma
EDAT- 2014/12/09 06:00
MHDA- 2015/10/27 06:00
PMCR- 2015/11/01
CRDT- 2014/12/09 06:00
PHST- 2014/12/09 06:00 [entrez]
PHST- 2014/12/09 06:00 [pubmed]
PHST- 2015/10/27 06:00 [medline]
PHST- 2015/11/01 00:00 [pmc-release]
AID - 984155 [pii]
AID - 10.4161/hv.29110 [doi]
PST - ppublish
SO  - Hum Vaccin Immunother. 2014;10(11):3132-8. doi: 10.4161/hv.29110.